Publications by authors named "Martin Highley"

Claim this Profile
A
A randomised phase 2 study of intermittent versus continuous dosing of dabrafenib plus trametinib in patients with BRAF mutant advanced melanoma (INTERIM).
Alimu Dayimu, Avinash Gupta, Rubeta N Matin, Jenny Nobes, Ruth Board, Martin Highley

Eur J Cancer· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Imaging Modality and Frequency in Surveillance of Stage I Seminoma Testicular Cancer: Results From a Randomized, Phase III, Noninferiority Trial (TRISST).
Johnathan K Joffe, Fay H Cafferty, Laura Murphy, Gordon J S Rustin, Syed A Sohaib, Martin Highley

J Clin Oncol· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Nitrogen Mustards.
Martin S Highley, Bart Landuyt, Hans Prenen, Peter G Harper, Ernst A De Bruijn

Pharmacol Rev· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Decrease of Pro-Angiogenic Monocytes Predicts Clinical Response to Anti-Angiogenic Treatment in Patients with Metastatic Renal Cell Carcinoma.
Stephane Oudard, Nadine Benhamouda, Bernard Escudier, Patrice Ravel, Thi Tran, Martin Highley

Cells· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial.
P G Corrie, A Marshall, P D Nathan, P Lorigan, M Gore, Martin Highley

Ann Oncol· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world treatment practice in patients with advanced melanoma in the era before ipilimumab: results from the IMAGE study.
Mark R Middleton, Stéphane Dalle, Joel Claveau, Pilar Mut, Sigrun Hallmeyer, Martin Highley

Cancer Med· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer.
Yvette Drew, Jonathan Ledermann, Geoff Hall, Daniel Rea, Ros Glasspool, Martin Highley

Br J Cancer· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer.
Yvette Drew, Jonathan Ledermann, Geoff Hall, Daniel Rea, Ros Glasspool, Martin Highley

Br J Cancer· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Five-year outcome for women randomised in a phase III trial comparing doxorubicin and cyclophosphamide with doxorubicin and docetaxel as primary medical therapy in early breast cancer: an Anglo-Celtic Cooperative Oncology Group study.
Janine L Mansi, Ann Yellowlees, Julian Lipscombe, Helena M Earl, David A Cameron, Martin Highley

Breast Cancer Res Treat· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CA 19-9 and survival in advanced and unresectable pancreatic adenocarcinoma and cholangiocarcinoma.
Clinton W Ali, Thomas F Kaye, Douglas J A Adamson, Iain S Tait, Francesco M Polignano, Martin S Highley

J Gastrointest Cancer· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Simultaneous determination of AMN107 and Imatinib (Gleevec, Glivec, STI571) in cultured tumour cells using an isocratic high-performance liquid chromatography procedure with UV detection.
Gunther Guetens, Hans Prenen, Gert De Boeck, Allan van Oosterom, Patrick Schöffski, Martin Highley

J Chromatogr B Analyt Technol Biomed Life Sci· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Everolimus alters imatinib blood partition in favour of the erythrocyte.
Hans Prenen, Gunther Guetens, Gert De Boeck, Martin Highley, Allan T van Oosterom

J Pharm Pharmacol· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Imatinib (Gleevec, Glivec) tumour tissue analysis by measurement of sediment and by liquid chromatography tandem mass spectrometry.
Gunther Guetens, Hans Prenen, Gert De Boeck, Martin Highley, Ivo de Wever

J Sep Sci· February 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro partition of docetaxel and gemcitabine in human volunteer blood: the influence of concentration and gender.
Herlinde Dumez, Gunther Guetens, Gert De Boeck, Martin S Highley, Ernst A de Bruijn

Anticancer Drugs· September 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro partition of irinotecan (CPT-11) in human volunteer blood: the influence of concentration, gender and smoking.
Herlinde Dumez, Gunther Guetens, Gert De Boeck, Martin S Highley, Ernst A de Bruijn

Anticancer Drugs· September 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an anglo-celtic cooperative oncology group study.
T R Jeffry Evans, Ann Yellowlees, Elizabeth Foster, Helena Earl, David A Cameron, Martin Highley

J Clin Oncol· May 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The relevance of therapeutic drug monitoring in plasma and erythrocytes in anti-cancer drug treatment.
Herlinde Dumez, Gunther Guetens, Gert De Boeck, Martin S Highley, Robert A A Maes

Clin Chem Lab Med· April 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vascular endothelial growth factor and angiogenesis.
Ann Hoeben, Bart Landuyt, Martin S Highley, Hans Wildiers, Allan T Van Oosterom

Pharmacol Rev· December 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacology of anticancer drugs in the elderly population.
Hans Wildiers, Martin S Highley, Ernst A de Bruijn, Allan T van Oosterom

Clin Pharmacokinet· March 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantification of the anticancer agent STI-571 in erythrocytes and plasma by measurement of sediment technology and liquid chromatography-tandem mass spectrometry.
Gunther Guetens, Gert De Boeck, Martin Highley, Herlinde Dumez, Allan T Van Oosterom

J Chromatogr A· December 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I trial of ZD9331, a water-soluble, nonpolyglutamatable, thymidylate synthase inhibitor.
Ruth Plummer, Charlotte Rees, Andrew Hughes, Philip Beale, Martin Highley

Clin Cancer Res· April 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oxidative DNA damage: biological significance and methods of analysis.
Gunther Guetens, Gert De Boeck, Martin Highley, Allan T van Oosterom, Ernst A de Bruijn

Crit Rev Clin Lab Sci· September 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Melphalan availability in hypoxia-inducible factor-1alpha+/+ and factor-1alpha-/- tumors is independent of tumor vessel density and correlates with melphalan erythrocyte transport.
Hans Wildiers, Gunter Guetens, Gert de Boeck, Willy Landuyt, Eric Verbeken, Martin Highley

Int J Cancer· June 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized cross-over clinical trial to study potential pharmacokinetic interactions between cisplatin or carboplatin and etoposide.
Huw D Thomas, David J Porter, Imke Bartelink, Joy R Nobbs, Michael Cole, Martin Highley

Br J Clin Pharmacol· January 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis